A Phase I/II, Multi-Center, Open Label Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced and Refractory Multiple Myeloma Patients.
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2016
At a glance
- Drugs Defibrotide (Primary) ; Melphalan; Prednisone; Thalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 09 May 2016 Status changed from discontinued to completed.
- 15 Sep 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Mar 2010 Planned end date (Oct 2006) added as reported by ClinicalTrials.gov.